Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2018; 8(3):644-649. doi:10.7150/thno.22161 This issue Cite

Research Paper

Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients

Constantin Lapa1,2✉, Malte Kircher1, Heribert Hänscheid1, Andreas Schirbel1, Götz Ulrich Grigoleit3, Erdwine Klinker4, Markus Böck4, Samuel Samnick1, Theo Pelzer2,5, Andreas K Buck1

1. Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany
2. Center for Rare Diseases - Reference Center Northern Bavaria (ZESE), Würzburg, Germany
3. Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
4. Institute for Transfusion Medicine and Hemotherapy, University Hospital Würzburg, Würzburg, Germany
5. Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany

✉ Corresponding author: lapa_cde

Citation:
Lapa C, Kircher M, Hänscheid H, Schirbel A, Grigoleit GU, Klinker E, Böck M, Samnick S, Pelzer T, Buck AK. Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients. Theranostics 2018; 8(3):644-649. doi:10.7150/thno.22161. https://www.thno.org/v08p0644.htm
Other styles

File import instruction

Abstract

Graphic abstract

Sarcoidosis is a multisystem granulomatous disorder of unknown etiology that can involve virtually all organ systems. Whereas most patients present without symptoms, progressive and disabling organ failure can occur in up to 10% of subjects. Somatostatin receptor (SSTR)-directed peptide receptor radionuclide therapy (PRRT) has recently received market authorization for treatment of SSTR-positive neuroendocrine tumors.

Methods: We describe the first case series comprising two patients with refractory multi-organ involvement of sarcoidosis who received 4 cycles of PRRT.

Results: PRRT was well-tolerated without any acute adverse effects. No relevant toxicities could be recorded during follow-up. Therapy resulted in partial response accompanied by a pronounced reduction in pain (patient #1) and stable disease regarding morphology as well as disease activity (patient #2), respectively.

Conclusion: Peptide receptor radionuclide therapy in sarcoidosis is feasible and might be a new valuable tool in patients with otherwise treatment-refractory disease. Given the long experience with and good tolerability of PRRT, further evaluation of this new treatment option for otherwise treatment-refractory sarcoidosis in larger patient cohorts is warranted.

Keywords: Sarcoidosis, somatostatin receptors, peptide receptor radionuclide therapy, PRRT

Citation styles

APA
Lapa, C., Kircher, M., Hänscheid, H., Schirbel, A., Grigoleit, G.U., Klinker, E., Böck, M., Samnick, S., Pelzer, T., Buck, A.K. (2018). Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients. Theranostics, 8(3), 644-649. https://doi.org/10.7150/thno.22161.

ACS
Lapa, C.; Kircher, M.; Hänscheid, H.; Schirbel, A.; Grigoleit, G.U.; Klinker, E.; Böck, M.; Samnick, S.; Pelzer, T.; Buck, A.K. Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients. Theranostics 2018, 8 (3), 644-649. DOI: 10.7150/thno.22161.

NLM
Lapa C, Kircher M, Hänscheid H, Schirbel A, Grigoleit GU, Klinker E, Böck M, Samnick S, Pelzer T, Buck AK. Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients. Theranostics 2018; 8(3):644-649. doi:10.7150/thno.22161. https://www.thno.org/v08p0644.htm

CSE
Lapa C, Kircher M, Hänscheid H, Schirbel A, Grigoleit GU, Klinker E, Böck M, Samnick S, Pelzer T, Buck AK. 2018. Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients. Theranostics. 8(3):644-649.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use